Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 27 | 2.590 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2022 | 18 | 2.440 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2022 | 21 | 1.930 |
Why?
|
| Endocarditis | 3 | 2022 | 6 | 1.800 |
Why?
|
| Heart Neoplasms | 3 | 2021 | 10 | 1.790 |
Why?
|
| Postoperative Complications | 7 | 2022 | 827 | 1.200 |
Why?
|
| Endocarditis, Bacterial | 2 | 2022 | 10 | 0.960 |
Why?
|
| Marfan Syndrome | 1 | 2023 | 4 | 0.850 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 10 | 0.830 |
Why?
|
| Humans | 36 | 2023 | 25692 | 0.820 |
Why?
|
| Aneurysm, False | 2 | 2016 | 7 | 0.820 |
Why?
|
| Pulmonary Valve | 1 | 2022 | 12 | 0.800 |
Why?
|
| Heart Ventricles | 4 | 2017 | 96 | 0.790 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2016 | 10 | 0.760 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2012 | 9 | 0.760 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 9 | 0.760 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 9 | 0.760 |
Why?
|
| Mesothelioma | 1 | 2021 | 13 | 0.750 |
Why?
|
| Stents | 2 | 2016 | 80 | 0.750 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2019 | 37 | 0.740 |
Why?
|
| Male | 23 | 2022 | 13917 | 0.730 |
Why?
|
| Hospital Mortality | 4 | 2020 | 131 | 0.720 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2020 | 11 | 0.720 |
Why?
|
| Female | 23 | 2023 | 14273 | 0.720 |
Why?
|
| Reoperation | 4 | 2022 | 818 | 0.710 |
Why?
|
| Heart Aneurysm | 2 | 2013 | 8 | 0.710 |
Why?
|
| Lung Diseases | 1 | 2020 | 42 | 0.710 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 32 | 0.690 |
Why?
|
| Aortic Valve | 5 | 2020 | 25 | 0.680 |
Why?
|
| Treatment Outcome | 10 | 2022 | 3231 | 0.650 |
Why?
|
| Coronary Artery Bypass | 4 | 2015 | 26 | 0.640 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 6 | 0.640 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 14 | 0.630 |
Why?
|
| Stroke | 1 | 2022 | 259 | 0.620 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 25 | 0.600 |
Why?
|
| Sternotomy | 2 | 2015 | 2 | 0.590 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3220 | 0.580 |
Why?
|
| Sarcoma | 1 | 2020 | 128 | 0.570 |
Why?
|
| Bioprosthesis | 2 | 2017 | 7 | 0.570 |
Why?
|
| Aged | 17 | 2021 | 8501 | 0.560 |
Why?
|
| United States | 6 | 2023 | 1943 | 0.560 |
Why?
|
| Middle Aged | 18 | 2021 | 8403 | 0.550 |
Why?
|
| Adult | 11 | 2023 | 7336 | 0.550 |
Why?
|
| Endarterectomy | 1 | 2016 | 1 | 0.550 |
Why?
|
| Intermittent Claudication | 1 | 2016 | 3 | 0.550 |
Why?
|
| Femoral Artery | 1 | 2016 | 3 | 0.550 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 6 | 0.540 |
Why?
|
| Heart Atria | 1 | 2016 | 26 | 0.540 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 49 | 0.540 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2016 | 12 | 0.530 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 509 | 0.530 |
Why?
|
| Cause of Death | 1 | 2016 | 63 | 0.530 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 33 | 0.510 |
Why?
|
| Thoracotomy | 2 | 2013 | 25 | 0.500 |
Why?
|
| Pneumopericardium | 1 | 2015 | 1 | 0.500 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 178 | 0.490 |
Why?
|
| Vascular Surgical Procedures | 2 | 2013 | 24 | 0.470 |
Why?
|
| Heart Failure | 2 | 2017 | 166 | 0.460 |
Why?
|
| Cardiopulmonary Bypass | 4 | 2016 | 19 | 0.440 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2013 | 1 | 0.440 |
Why?
|
| Sinus of Valsalva | 1 | 2013 | 4 | 0.440 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 22 | 0.420 |
Why?
|
| Calcinosis | 1 | 2013 | 48 | 0.420 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 126 | 0.400 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 16 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 698 | 0.370 |
Why?
|
| Fibroma | 1 | 2011 | 5 | 0.370 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 13 | 0.370 |
Why?
|
| Hospitalization | 2 | 2023 | 292 | 0.350 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 475 | 0.340 |
Why?
|
| Risk Assessment | 3 | 2019 | 618 | 0.330 |
Why?
|
| Hemorrhage | 2 | 2020 | 75 | 0.330 |
Why?
|
| Heart Arrest, Induced | 3 | 2013 | 3 | 0.320 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 129 | 0.310 |
Why?
|
| Pericarditis | 1 | 2007 | 1 | 0.280 |
Why?
|
| Risk Factors | 4 | 2022 | 2224 | 0.250 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4459 | 0.230 |
Why?
|
| Arterioles | 3 | 2012 | 12 | 0.220 |
Why?
|
| Biopsy | 2 | 2016 | 199 | 0.220 |
Why?
|
| Postpartum Period | 1 | 2023 | 17 | 0.210 |
Why?
|
| Catheterization | 1 | 2022 | 39 | 0.210 |
Why?
|
| Lower Extremity | 1 | 2022 | 39 | 0.200 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2016 | 3 | 0.200 |
Why?
|
| Length of Stay | 2 | 2022 | 300 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 35 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 129 | 0.190 |
Why?
|
| Propensity Score | 1 | 2021 | 32 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2022 | 115 | 0.180 |
Why?
|
| Aorta | 2 | 2021 | 15 | 0.180 |
Why?
|
| SEER Program | 1 | 2020 | 37 | 0.180 |
Why?
|
| Incidence | 1 | 2023 | 731 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 177 | 0.180 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 37 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 10 | 0.180 |
Why?
|
| Adipose Tissue | 1 | 2021 | 69 | 0.170 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1689 | 0.170 |
Why?
|
| Myocardium | 2 | 2013 | 95 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 341 | 0.170 |
Why?
|
| Young Adult | 3 | 2020 | 1855 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 332 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 37 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 315 | 0.160 |
Why?
|
| Heparin | 1 | 2019 | 20 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 119 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2019 | 88 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 739 | 0.150 |
Why?
|
| Time Factors | 3 | 2016 | 1336 | 0.150 |
Why?
|
| Infant | 1 | 2020 | 529 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 110 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2020 | 640 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2020 | 588 | 0.150 |
Why?
|
| Heart Transplantation | 1 | 2017 | 29 | 0.140 |
Why?
|
| Adolescent | 2 | 2020 | 2076 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2017 | 63 | 0.140 |
Why?
|
| Polyethylene Terephthalates | 1 | 2017 | 3 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2017 | 12 | 0.140 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Heterografts | 1 | 2016 | 12 | 0.140 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2016 | 15 | 0.140 |
Why?
|
| Swine | 1 | 2016 | 71 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2016 | 246 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 148 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 157 | 0.130 |
Why?
|
| Time Out, Healthcare | 1 | 2016 | 1 | 0.130 |
Why?
|
| Operating Rooms | 1 | 2016 | 15 | 0.130 |
Why?
|
| Checklist | 1 | 2016 | 30 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1277 | 0.130 |
Why?
|
| Survival Rate | 2 | 2017 | 308 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 329 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 1781 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 32 | 0.110 |
Why?
|
| Moon | 1 | 2013 | 2 | 0.110 |
Why?
|
| Depression | 1 | 2017 | 412 | 0.110 |
Why?
|
| Heart Bypass, Left | 1 | 2013 | 1 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 180 | 0.110 |
Why?
|
| Seasons | 1 | 2013 | 23 | 0.110 |
Why?
|
| Atrial Appendage | 1 | 2013 | 29 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2013 | 43 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 280 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 913 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2013 | 38 | 0.100 |
Why?
|
| Vasodilation | 1 | 2012 | 5 | 0.100 |
Why?
|
| Microcirculation | 1 | 2012 | 28 | 0.100 |
Why?
|
| Apoptosis | 1 | 2013 | 177 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 35 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2012 | 33 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2012 | 10 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 383 | 0.100 |
Why?
|
| Thromboxane A2 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Radiography | 1 | 2013 | 574 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 28 | 0.090 |
Why?
|
| Muscle Contraction | 1 | 2011 | 65 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 8 | 0.090 |
Why?
|
| Echocardiography | 1 | 2011 | 88 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 69 | 0.090 |
Why?
|
| Animals | 1 | 2016 | 3510 | 0.080 |
Why?
|
| Fibrosis | 1 | 2007 | 28 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 69 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2007 | 67 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 11 | 0.060 |
Why?
|
| Inflammation | 2 | 2021 | 261 | 0.060 |
Why?
|
| Disease Progression | 1 | 2006 | 664 | 0.050 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2013 | 2 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2012 | 47 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 19 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 51 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2021 | 74 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 18 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 65 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 33 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 128 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2021 | 55 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 150 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 136 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 14 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 290 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 50 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 80 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 216 | 0.030 |
Why?
|
| Systems Theory | 1 | 2016 | 3 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 27 | 0.030 |
Why?
|
| Medication Errors | 1 | 2016 | 14 | 0.030 |
Why?
|
| Medical Errors | 1 | 2016 | 25 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2016 | 41 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 49 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 447 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2016 | 132 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 130 | 0.030 |
Why?
|
| Cardioplegic Solutions | 1 | 2013 | 1 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 12 | 0.030 |
Why?
|
| Rhode Island | 1 | 2013 | 2 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 33 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 24 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 108 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 869 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2012 | 5 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2012 | 5 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2012 | 18 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2012 | 11 | 0.030 |
Why?
|
| Substance P | 1 | 2012 | 12 | 0.030 |
Why?
|
| Tyrosine | 1 | 2012 | 25 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 231 | 0.030 |
Why?
|
| Protein Kinase C-alpha | 1 | 2012 | 8 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2012 | 8 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 32 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 244 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 36 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 26 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 299 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2012 | 134 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 366 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 60 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2012 | 50 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 51 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 392 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 427 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 182 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 262 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 532 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 554 | 0.020 |
Why?
|